The II Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19 Joint Guidelines of the Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia and Sociedade Brasileira de Reumatologia.

Autor:	Falavigna M; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Araujo CLP; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Barbosa AN; Sociedade Brasileira de Infectologia - São Paulo (SP), Brazil., Belli KC; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Colpani V; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Dal-Pizzol F; Universidade do Extremo Sul Catarinense - Criciúma (SC), Brazil., Silva RMD; Sociedade Brasileira de Pneumologia e Tisiologia - São Paulo (SP), Brazil., Azevedo LCP; Hospital de Clínicas, Faculdade de Medicina, Universidade de São Paulo - São Paulo (SP), Brazil., Dias MBS; Hospital de Clínicas, Faculdade de Medicina, Universidade de São Paulo - São Paulo (SP), Brazil., Amaral JLGD; Associação Médica Brasileira - São Paulo (SP), Brazil., Dorneles GP; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Ferreira JC; Sociedade Brasileira de Pneumologia e Tisiologia - São Paulo (SP), Brazil.; Associação de Medicina Intensiva Brasileira - São Paulo (SP), Brazil., Freitas APDR; Associação Brasileira de Medicina de Emergência - São Paulo (SP), Brazil., Gräf DD; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Guimarães HP; Associação Brasileira de Medicina de Emergência - São Paulo (SP), Brazil., Lobo SMA; Associação de Medicina Intensiva Brasileira - São Paulo (SP), Brazil., Machado FR; Associação de Medicina Intensiva Brasileira - São Paulo (SP), Brazil., Nunes MS; Associação de Medicina Intensiva Brasileira - São Paulo (SP), Brazil., Oliveira MS; Associação Médica Brasileira - São Paulo (SP), Brazil., Parahiba SM; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Rosa RG; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Santos VCC; Ministério da Gestão e da Inovação em Serviços Públicos - Brasília (DF), Brazil., Sobreira ML; Sociedade Brasileira de Angiologia e de Cirurgia Vascular - São Paulo (SP), Brazil., Veiga VC; Associação de Medicina Intensiva Brasileira - São Paulo (SP), Brazil., Xavier RM; Sociedade Brasileira de Reumatologia - São Paulo (SP), Brazil., Zavascki AP; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Stein C; Hospital Moinhos de Vento - Porto Alegre (RS), Brazil., Carvalho CRR; Associação Médica Brasileira - São Paulo (SP), Brazil.
Jazyk:	English; Portuguese
Zdroj:	Critical care science [Crit Care Sci] 2023 Dec 22; Vol. 35 (3), pp. 243-255. Date of Electronic Publication: 2023 Dec 22 (Print Publication: 2023).
DOI:	10.5935/2965-2774.20230136-en
Abstrakt:	Objective: To update the recommendations to support decisions regarding the pharmacological treatment of patients hospitalized with COVID-19 in Brazil. Methods: Experts, including representatives of the Ministry of Health and methodologists, created this guideline. The method used for the rapid development of guidelines was based on the adoption and/or adaptation of existing international guidelines (GRADE ADOLOPMENT) and supported by the e-COVID-19 RecMap platform. The quality of the evidence and the preparation of the recommendations followed the GRADE method. Results: Twenty-one recommendations were generated, including strong recommendations for the use of corticosteroids in patients using supplemental oxygen and conditional recommendations for the use of tocilizumab and baricitinib for patients on supplemental oxygen or on noninvasive ventilation and anticoagulants to prevent thromboembolism. Due to suspension of use authorization, it was not possible to make recommendations regarding the use of casirivimab + imdevimab. Strong recommendations against the use of azithromycin in patients without suspected bacterial infection, hydroxychloroquine, convalescent plasma, colchicine, and lopinavir + ritonavir and conditional recommendations against the use of ivermectin and remdesivir were made. Conclusion: New recommendations for the treatment of hospitalized patients with COVID-19 were generated, such as those for tocilizumab and baricitinib. Corticosteroids and prophylaxis for thromboembolism are still recommended, the latter with conditional recommendation. Several drugs were considered ineffective and should not be used to provide the best treatment according to the principles of evidence-based medicine and to promote resource economy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu